Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.

Bentzen, Jens; Toustrup, Kasper; Eriksen, Jesper Grau; Primdahl, Hanne; Andersen, Lisbeth Juhler; Overgaard, Jens

Bentzen, Jens; Toustrup, Kasper; Eriksen, Jesper Grau; Primdahl, Hanne; Andersen, Lisbeth Juhler; Overgaard, Jens.

Affiliation

Bentzen J; Department of Oncology, Herlev Hospital , Herlev , Denmark.

Acta Oncol ; 54(7): 1001-7, 2015 Jul.

Article in En | MEDLINE | ID: mdl-25629651

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carcinoma, Squamous Cell/drug therapy; Carcinoma, Squamous Cell/radiotherapy; Chemoradiotherapy/methods; Head and Neck Neoplasms/drug therapy; Head and Neck Neoplasms/radiotherapy; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Carcinoma, Squamous Cell/mortality; Chemoradiotherapy/adverse effects; Cisplatin/administration & dosage; Cisplatin/adverse effects; Disease-Free Survival; Female; Head and Neck Neoplasms/mortality; Humans; Male; Middle Aged; Nimorazole/administration & dosage; Nimorazole/adverse effects; Squamous Cell Carcinoma of Head and Neck

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Squamous Cell / Antineoplastic Combined Chemotherapy Protocols / Chemoradiotherapy / Head and Neck Neoplasms Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2015 Type: Article

Fulltext

XML

PubMed Links

Search on Google